Physicochemical Properties
| Molecular Formula | C14H16NO6CL |
| Molecular Weight | 329.73294 |
| Exact Mass | 329.066 |
| CAS # | 138182-21-5 |
| PubChem CID | 7567562 |
| Appearance | White to off-white solid powder |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 630.2±55.0 °C at 760 mmHg |
| Flash Point | 335.0±31.5 °C |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.717 |
| LogP | -0.15 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 22 |
| Complexity | 388 |
| Defined Atom Stereocenter Count | 5 |
| SMILES | C1=CC2=C(C=C1Cl)NC=C2O[C@H]3[C@@H]([C@H]([C@H]([C@@H](CO)O3)O)O)O |
| InChi Key | OQWBAXBVBGNSPW-MBJXGIAVSA-N |
| InChi Code | InChI=1S/C14H16ClNO6/c15-6-1-2-7-8(3-6)16-4-9(7)21-14-13(20)12(19)11(18)10(5-17)22-14/h1-4,10-14,16-20H,5H2/t10-,11+,12+,13-,14-/m1/s1 |
| Chemical Name | (2S,3R,4S,5R,6R)-2-[(6-chloro-1H-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Advice (This is our suggested protocol, which should be adjusted to suit your particular circumstances as it simply offers guidance). Immunostaining of tissue[1][2]: 1. Make a stock solution of 25 mg/mL Rose-β-D-Gal in dimethyl sulfoxide (DMSO) and keep it refrigerated at -20°C. It's critical to keep light away from the stock solution. 2. Assemble the washing buffer for Rose-β-D-Gal staining: 0.1 M sodium phosphate buffer (pH 7.3) containing 0.1% sodium deoxycholate, 0.2% IGEPAL CA-630, and 2 mM magnesium chloride. Mix 158 mL of 1 M NaHPO4, 342 mL of 1 M NaHPO4, and 500 mL of water to make 1,000 mL of 0.5 M sodium phosphate buffer (pH 7.3). 3. In the wash buffer, combine 1 mg/mL of Rose-β-D-Gal, 5 mM potassium ferricyanide, and 5 mM potassium ferricyanide to create a new Rose-β-D-Gal substrate solution. 4. Rehydrate the frozen tissue sections by washing them three times for ten minutes with wash buffer and twice immediately with PBS. 5. Exposure to Rose-β-D-Gal β-galactosidase substrate: Stain at 37°C for as long as required to observe staining, up to one night; during development, keep covered and in the dark. 6. Do a five-minute PBS wash twice. Unless you intend to continue with in situ hybridization, fix the tissue in 4% PFA and move on to step 4. Rose-β-D-Gal is unstable in alcohols and organic solvents, so coverslipping with aqueous mounting solution is required when using aqueous counterstains like Gil's hematoxylin. |
| References |
[1]. Immunohistologic labeling of murine endothelium. 2003, 12(2):0-90. [2]. In situ hybridization methods for mouse whole mounts and tissue sections with and without additional β-galactosidase staining. Methods Mol Biol. 2014;1092:1-15. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0328 mL | 15.1639 mL | 30.3278 mL | |
| 5 mM | 0.6066 mL | 3.0328 mL | 6.0656 mL | |
| 10 mM | 0.3033 mL | 1.5164 mL | 3.0328 mL |